Schmandt Mathias, Glowka Tim R, Kreyer Stefan, Muders Thomas, Muenster Stefan, Theuerkauf Nils Ulrich, Kalff Jörg C, Putensen Christian, Schewe Jens-Christian, Ehrentraut Stefan Felix
Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, 53127 Bonn, Germany.
Department of Surgery, University Hospital Bonn, 53127 Bonn, Germany.
J Clin Med. 2021 Mar 2;10(5):1000. doi: 10.3390/jcm10051000.
To assess the feasibility of extracorporeal membrane oxygenation (ECMO) or life support (ECLS) as last resort life support therapy in patients with acute pancreatitis and subsequent secondary acute respiratory distress syndrome (ARDS).
Retrospective analysis from January 2013, to April 2020, of ECMO patients with pancreatitis-induced ARDS at a German University Hospital. Demographics, hospital and ICU length of stay, duration of ECMO therapy, days on mechanical ventilation, fluid balance, need for decompressive laparotomy, amount of blood products, prognostic scores (CCI (Charlson Comorbidity Index), SOFA (Sequential Organ Failure Assessment), RESP(Respiratory ECMO Survival Prediction), SAVE (Survival after Veno-Arterial ECMO)), and the total known length of survival were assessed.
A total of = 495 patients underwent ECMO. Eight patients with acute pancreatitis received ECLS (seven veno-venous, one veno-arterial). Five (71%) required decompressive laparotomy as salvage therapy due to abdominal hypertension. Two patients with acute pancreatitis (25%) survived to hospital discharge. The overall median length of survival was 22 days. Survivors required less fluid in the first 72 h of ECMO support and showed lower values for all prognostic scores.
ECLS can be performed as a rescue therapy in patients with pancreatitis and secondary ARDS, but nevertheless mortality remains still high. Thus, this last-resort therapy may be best suited for patients with fewer pre-existing comorbidities and no other organ failure.
评估体外膜肺氧合(ECMO)或体外生命支持(ECLS)作为急性胰腺炎及随后继发急性呼吸窘迫综合征(ARDS)患者的最后手段生命支持治疗的可行性。
回顾性分析2013年1月至2020年4月在德国一家大学医院接受ECMO治疗的胰腺炎诱导型ARDS患者。评估人口统计学资料、住院和重症监护病房(ICU)住院时间、ECMO治疗持续时间、机械通气天数、液体平衡、减压剖腹手术需求、血液制品用量、预后评分(Charlson合并症指数(CCI)、序贯器官衰竭评估(SOFA)、呼吸ECMO生存预测(RESP)、静脉-动脉ECMO后生存率(SAVE))以及已知的总生存时长。
共有495例患者接受了ECMO治疗。8例急性胰腺炎患者接受了ECLS治疗(7例静脉-静脉,1例静脉-动脉)。5例(71%)因腹腔高压需要进行减压剖腹手术作为挽救治疗。2例急性胰腺炎患者(25%)存活至出院。总体生存中位数为22天。幸存者在ECMO支持的前72小时需要的液体较少,且所有预后评分的值较低。
ECLS可作为胰腺炎继发ARDS患者的挽救治疗,但死亡率仍然很高。因此,这种最后手段治疗可能最适合合并症较少且无其他器官衰竭的患者。